Document text
Principal Investigator: Natalie Lea Silver
Organization: UNIVERSITY OF FLORIDA
Fiscal Year: 2020
Award: $155,304
Funding agency: National Institute of Dental and Craniofacial Research
PROJECT SUMMARY/ABSTRACT
Oral cavity squamous cell carcinoma (OCSCC) is a very aggressive and deadly disease with poor survival
rates following maximal treatments such as surgery and chemoradiotherapy. The immunosuppressive tumor
microenvironment (TME) is a major barrier of response to traditional and immune based therapies with only
~15% of patients with recurrent head and neck cancer responding to immune checkpoint inhibitors. Myeloid cells
are; abundant in the TME, key mediators of T cell function, and can influence clinical outcomes both positively
and negatively. We seek to understand the contribution of myeloid cells to the immunosuppressive TME and
advance strategies to modulate these cells in a favorable way, to enhance OCSCC tumor killing.
Our group has developed a novel vaccine treatment platform that can reprogram the intratumoral and
peripheral myeloid cell compartment to an anti-tumor state. This platform leverages the use of clinically
translatable lipid nanoparticles (NPs), combined with personalized tumor derived mRNA (TDRNA) that
simultaneously functions as both a vaccine and an immunomodulating agent. We have demonstrated that
TDRNA-NP vaccines have significant anti-tumor activity in OCSCC preclinical models and synergize with
immune checkpoint inhibitors. In Aim 1, we will determine the mechanism of TDRNA-NP induced myeloid cell
mediated immune responses by investigating vaccine induced myeloid cell proliferation, activation and
trafficking in preclinical models of OCSCC. In Aim 2, we will identify the mechanistic role of myeloid cells
in the synergy between TDRNA-NP vaccines and immune checkpoint inhibitors in murine models of
OCSCC. In Aim 3, we will examine the safety, efficacy and immunogenicity of TDRNA-NPs in client-owned
felines with spontaneously occurring oral squamous cell carcinoma. These studies will give us insight into
the role of the myeloid cell compartment in OCSCC and advance a promising vaccine technology towards
first-in-human clinical trials. The P.I. of this project is a head and neck surgical oncologist and
witnesses the daily impact head and neck cancer has on patients and recognizes the need to
improve patient care through translational research. She is an active member of the Head and Neck
oncology program, is strongly supported by her department, and has a mentoring team comprised of world
renowned expert tumor immunologist/translational researchers, and head and neck surgeon-scientists. This
mentored training and educational program has been carefully designed with research and career objectives
that will allow the P.I. to progress toward becoming an expert head and neck cancer immunologist and
translational researcher. In summary, this proposal has significant potential to dramatically impact the lives
of patients with OCSCC and will provide substantial training and mentorship for the P.I. to become an
independent investigator.
Terms: <Antigen-Presenting Cells><B7-H1><B7H1><Biology><Blood><Blood Reticuloendothelial System><CD274><Cancer Model><Cancer Patient><CancerModel><Career Development Awards><Career Development Awards and Programs><Career Development Programs K-Series><Cats><Cats Mammals><Cell Body><Cell Compartmentation><Cell Compartmentations><Cell Function><Cell Growth in Number><Cell Multiplication><Cell Process><Cell Proliferation><Cell physiology><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular Proliferation><Checkpoint inhibitor><Client><Clinical><Clinical Trials><Clinical Trials Design><Collaborations><Dendritic Cells><Disease><Disorder><Domestic Cats><Dose><Family Felidae><Felidae><Felids><Feline Species><Felis catus><Felis domestica><Felis domesticus><Felis sylvestris catus><Gamma interferon><Gene Transcription><Genetic Transcription><HNC patient><Head and Neck><Head and Neck Cancer><Head and Neck Surgeon><Head and neck structure><Human><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><IMiD><Immune Cell Activation><Immune Interferon><Immune checkpoint inhibitor><Immune mediated therapy><Immune modulatory therapeutic><Immune response><Immunity><Immunobiology><Immunochemical Immunologic><Immunologic><Immunological><Immunological response><Immunologically><Immunologically Directed Therapy><Immunologics><Immunologist><Immunomodulators><Immunophysiology><Immunotherapy><Interferon Gamma><Interferon Type II><Interferon-gamma><Intravenous><Investigation><Investigators><K-Awards><K-Series Research Career Programs><Knowledge><Malignant Head and Neck Neoplasm><Malignant Oral Cavity Neoplasm><Malignant Oral Cavity Tumor><Malignant Oral Neoplasm><Mediating><Mediator><Mediator of Activation><Mediator of activation protein><Mentors><Mentorship><Messenger RNA><Metastatic/Recurrent><Mice><Mice Mammals><Modeling><Modern Man><Mouth Cancer><Murine><Mus><Myelogenous><Myeloid><Myeloid Cell Activation><Myeloid Cells><Myeloid-derived suppressor cells><Non-Polyadenylated RNA><Oncologic Surgeon><Operative Procedures><Operative Surgical Procedures><Oral Cancer><Oral Cavity Squamous Cell Carcinoma><Oral squamous cell carcinoma><Outcome><PD-L1><PDL-1><PDL1><Patient Care><Patient Care Delivery><Patients><Peripheral><Phase><Play><Pre-Clinical Model><Pre-clinical Drug Testing/Development><Preclinical Drug Development><Preclinical Drug Testing/Development><Preclinical Models><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Property><RNA><RNA Expression><RNA Gene Products><Recurrence><Recurrent><Recurrent Cancer><Recurrent Malignant Neoplasm><Recurrent Malignant Tumor><Regulatory T-Lymphocyte><Research><Research Career Program><Research Personnel><Researchers><Ribonucleic Acid><Role><Safety><Scientist><Solid Neoplasm><Solid Tumor><Subcellular Process><Surgical><Surgical Interventions><Surgical Oncologist><Surgical Procedure><Survival Rate><T-Cells><T-Lymphocyte><Technology><Testing><Therapeutic><Therapeutic Effect><Time><Training><Transcription><Translating><Translational Research><Translational Science><Translations><Treg><Tumor Immunity><Tumor Volume><Tumor-Derived><Vaccines><Veiled Cells><Veterinary Medicine><Work><accessory cell><anti-tumor immunity><antigen-specific T cells><antitumor immunity><cancer immunity><cancer microenvironment><career><cell mediated immune response><check point blockade><checkpoint blockade><chemo-/radio-therapy><chemo-radio-therapy><chemo-radiotherapy><chemoradiation><chemoradiotherapy><clinical significance><clinically significant><clinically translatable><college><collegiate><design><designing><effector T cell><feline><first in man><first-in-human><head and neck cancer patient><head impact><head/neck cancer><host response><immune activation><immune check point blockade><immune check point inhibitor><immune checkpoint blockade><immune microenvironment><immune modulating agents><immune modulating drug><immune modulating therapeutics><immune modulators><immune modulatory agents><immune modulatory drugs><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunogenicity><immunomodulating agents><immunomodulatory agents><immunomodulatory drugs><immunomodulatory therapeutics><immunoresponse><immunosuppressive microenvironment><immunosuppressive myeloid cells><immunosuppressive tumor microenvironment><improved><insight><lFN-Gamma><lipid nanoparticle><mRNA><macrophage><malignant head and neck tumor><malignant mouth neoplasm><malignant mouth tumor><member><mouse model><mouth SCC><mouth squamous cell carcinoma><murine model><nano particle><nano-sized particle><nanoparticle><nanosized particle><new approaches><new vaccines><next generation vaccines><novel><novel approaches><novel strategies><novel strategy><novel vaccines><oncology program><oral cavity SCC><oral cavity cancer><oral squamous cancer><oral squamous carcinoma><patient population><pet animal><pets><pre-clinical><pre-clinical drug development><preclinical><programmed cell death ligand 1><programmed cell death protein ligand 1><programs><radio-chemo-therapy><radio-chemotherapy><radiochemotherapy><regulatory T-cells><resistance to therapy><resistant to therapy><response><social role><suppressive myeloid cells><surgery><synergism><therapeutic resistance><therapeutic vaccine><therapy resistant><thymus derived lymphocyte><trafficking><translation research><translational investigator><translational researcher><translational scientist><treatment resistance><treatment vaccines><tumor><tumor immune microenvironment><tumor microenvironment><tumor-immune system interactions><vaccine efficacy><vaccine for the treatment><vaccine for treatment>